Endocrine Related Cancer · 2010 · 41 citations · 55 references
Life SciencesMolecular BiologyOncologyCell SignalingSignal TransductionTumor ProgressionCancer Cell SignalingCytokine BiologyCytokine SignalingGrowth Factor SignalingCellular ProliferationCytokine Signaling In CancerMapk SignalingProliferation PathwaysProtein Phosphorylation CascadesStat3 Signaling
Fibroblast growth factor-2 (FGF-2) is highly expressed in prostate cancer. It promotes tumour progression through multiple pathways including those of signal transducers and activators of transcription factor 3 (STAT3), mitogen-activated protein kinases (MAPKs) and Akt. In previous studies, we have reported that STAT3 phosphorylation inversely correlates with suppressor of cytokine signalling-3 (SOCS-3) expression in prostate cancer cells. Recently, it has become evident that SOCS-3-negative regulation is not only limited to the interleukin-6 (IL-6) receptor. We hypothesised that SOCS-3 interferes with FGF signalling, thus influencing the outcome of its action in prostate cancer cells. For this purpose, we treated DU-145 and LNCaP-IL-6+ cells with increasing concentrations of FGF-2, and verified protein phosphorylation. In the presence of FGF-2, neither STAT3, STAT1, nor Akt could be phosphorylated. Solely the p44/p42 MAPK pathway was activated after FGF-2 stimulation. We show for the first time that SOCS-3 interferes with the FGF-2 signalling pathway by modulating p44 and p42 phosphorylation in prostate cancer cells. Decreased SOCS-3 protein expression results in increased MAPK phosphorylation, whereas SOCS-3 overexpression leads to a decreased cellular proliferation and migration. On the basis of the present results, we propose that SOCS-3 is a novel modulator of FGF-2-regulated cellular events in prostate cancer.
55
Receptor Specificity of the Fibroblast Growth Factor Family
David M. Ornitz, Jennifer S. Colvin, Donald G. McEwen et al. · Journal of Biological Chemistry · 1996 · 1.9K citations · Full text
Activation of mitogen-activated protein kinase associated with prostate cancer progression.
Daniel Gioeli, James W. Mandell, Gina R. Petroni et al. · PubMed · 1999 · 541 citations